Which has preferable valuation & earnings, ANTX or SCYX?

SCYNEXIS has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.10 N/A SCYNEXIS $20.60M 2.33 -$8.61M -$3.84 N/A

Is ANTX or SCYX more profitable?

Anthem has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -50.54% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -52.35% -47.25% SCYNEXIS -41.79% -50.54% -34.22%

Is SCYX or ACOG more profitable?

SCYNEXIS has a net margin of -41.79% compared to Alpha Cognition's net margin of -232.23%. SCYNEXIS's return on equity of -50.54% beat Alpha Cognition's return on equity. Company Net Margins Return on Equity Return on Assets SCYNEXIS -41.79% -50.54% -34.22% Alpha Cognition -232.23% -58.35% -45.99%

Does the media prefer SCYX or ACOG?

In the previous week, SCYNEXIS had 4 more articles in the media than Alpha Cognition. MarketBeat recorded 7 mentions for SCYNEXIS and 3 mentions for Alpha Cognition. SCYNEXIS's average media sentiment score of 0.87 beat Alpha Cognition's score of 0.72 indicating that SCYNEXIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alpha Cognition 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SCYX or SBTX?

SCYNEXIS presently has a consensus target price of $24.00, suggesting a potential upside of 395.87%. Given SCYNEXIS's stronger consensus rating and higher possible upside, research analysts plainly believe SCYNEXIS is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, IMUX or SCYX?

SCYNEXIS has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$5.58 N/A SCYNEXIS $20.60M 2.33 -$8.61M -$3.84 N/A

Is IMUX or SCYX more profitable?

Immunic has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -50.54% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% SCYNEXIS -41.79% -50.54% -34.22%

Does the media prefer IMUX or SCYX?

In the previous week, Immunic and Immunic both had 7 articles in the media. Immunic's average media sentiment score of 1.01 beat SCYNEXIS's score of 0.87 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SCYNEXIS 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NERV or SCYX?

In the previous week, Minerva Neurosciences had 9 more articles in the media than SCYNEXIS. MarketBeat recorded 16 mentions for Minerva Neurosciences and 7 mentions for SCYNEXIS. Minerva Neurosciences' average media sentiment score of 1.04 beat SCYNEXIS's score of 0.87 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SCYNEXIS 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

SCYNEXIS (SCYX) Competitors

$4.84 -0.32 (-6.20%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$4.82 -0.01 (-0.31%)

As of 08/11/2026 07:52 PM Eastern

Compare

SCYX vs. ANTX, ACOG, SBTX, IMUX, and NERV

Should you buy SCYNEXIS stock or one of its competitors? SCYNEXIS's main competitors and comparable companies include Anthem (ANTX), Alpha Cognition (ACOG), Silverback Therapeutics (SBTX), Immunic (IMUX), and Minerva Neurosciences (NERV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does SCYNEXIS compare to Anthem?

Anthem (NASDAQ:ANTX) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, SCYNEXIS had 5 more articles in the media than Anthem. MarketBeat recorded 7 mentions for SCYNEXIS and 2 mentions for Anthem. SCYNEXIS's average media sentiment score of 0.87 beat Anthem's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Overall Sentiment
Anthem	Neutral
SCYNEXIS	Positive

SCYNEXIS has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A
SCYNEXIS	$20.60M	2.33	-$8.61M	-$3.84	N/A

Anthem has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Anthem presently has a consensus target price of $9.00, suggesting a potential upside of 53.32%. SCYNEXIS has a consensus target price of $24.00, suggesting a potential upside of 395.87%. Given SCYNEXIS's higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Anthem has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -50.54% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-52.35%	-47.25%
SCYNEXIS	-41.79%	-50.54%	-34.22%

90.5% of Anthem shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 22.6% of Anthem shares are owned by insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

SCYNEXIS beats Anthem on 9 of the 13 factors compared between the two stocks.

How does SCYNEXIS compare to Alpha Cognition?

SCYNEXIS (NASDAQ:SCYX) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

In the previous week, SCYNEXIS had 4 more articles in the media than Alpha Cognition. MarketBeat recorded 7 mentions for SCYNEXIS and 3 mentions for Alpha Cognition. SCYNEXIS's average media sentiment score of 0.87 beat Alpha Cognition's score of 0.72 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Cognition	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SCYNEXIS has a net margin of -41.79% compared to Alpha Cognition's net margin of -232.23%. SCYNEXIS's return on equity of -50.54% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-50.54%	-34.22%
Alpha Cognition	-232.23%	-58.35%	-45.99%

SCYNEXIS has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

SCYNEXIS currently has a consensus target price of $24.00, suggesting a potential upside of 395.87%. Alpha Cognition has a consensus target price of $16.00, suggesting a potential upside of 79.98%. Given SCYNEXIS's higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

54.4% of SCYNEXIS shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by company insiders. Comparatively, 8.6% of Alpha Cognition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

SCYNEXIS has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.33	-$8.61M	-$3.84	N/A
Alpha Cognition	$10.22M	18.94	-$20.67M	-$1.35	N/A

Summary

SCYNEXIS beats Alpha Cognition on 10 of the 16 factors compared between the two stocks.

How does SCYNEXIS compare to Silverback Therapeutics?

SCYNEXIS (NASDAQ:SCYX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

In the previous week, SCYNEXIS had 7 more articles in the media than Silverback Therapeutics. MarketBeat recorded 7 mentions for SCYNEXIS and 0 mentions for Silverback Therapeutics. SCYNEXIS's average media sentiment score of 0.87 beat Silverback Therapeutics' score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Overall Sentiment
SCYNEXIS	Positive
Silverback Therapeutics	Neutral

SCYNEXIS has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.33	-$8.61M	-$3.84	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Silverback Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Silverback Therapeutics' return on equity of -29.62% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-50.54%	-34.22%
Silverback Therapeutics	N/A	-29.62%	-28.20%

SCYNEXIS has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

SCYNEXIS presently has a consensus target price of $24.00, suggesting a potential upside of 395.87%. Given SCYNEXIS's stronger consensus rating and higher possible upside, research analysts plainly believe SCYNEXIS is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

SCYNEXIS beats Silverback Therapeutics on 9 of the 15 factors compared between the two stocks.

How does SCYNEXIS compare to Immunic?

Immunic (NASDAQ:IMUX) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

51.8% of Immunic shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Immunic has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Immunic presently has a consensus price target of $47.57, indicating a potential upside of 207.31%. SCYNEXIS has a consensus price target of $24.00, indicating a potential upside of 395.87%. Given SCYNEXIS's higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Immunic and Immunic both had 7 articles in the media. Immunic's average media sentiment score of 1.01 beat SCYNEXIS's score of 0.87 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunic has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -50.54% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
SCYNEXIS	-41.79%	-50.54%	-34.22%

SCYNEXIS has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
SCYNEXIS	$20.60M	2.33	-$8.61M	-$3.84	N/A

Summary

SCYNEXIS beats Immunic on 8 of the 15 factors compared between the two stocks.

How does SCYNEXIS compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

Minerva Neurosciences currently has a consensus price target of $10.50, suggesting a potential upside of 143.06%. SCYNEXIS has a consensus price target of $24.00, suggesting a potential upside of 395.87%. Given SCYNEXIS's stronger consensus rating and higher possible upside, analysts clearly believe SCYNEXIS is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Minerva Neurosciences had 9 more articles in the media than SCYNEXIS. MarketBeat recorded 16 mentions for Minerva Neurosciences and 7 mentions for SCYNEXIS. Minerva Neurosciences' average media sentiment score of 1.04 beat SCYNEXIS's score of 0.87 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Minerva Neurosciences has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Minerva Neurosciences' return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-34.07%
SCYNEXIS	-41.79%	-50.54%	-34.22%

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by insiders. Comparatively, 4.1% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

SCYNEXIS has higher revenue and earnings than Minerva Neurosciences. SCYNEXIS is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
SCYNEXIS	$20.60M	2.33	-$8.61M	-$3.84	N/A

Minerva Neurosciences has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Summary

SCYNEXIS beats Minerva Neurosciences on 9 of the 15 factors compared between the two stocks.

Get SCYNEXIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCYX vs. The Competition

Export

Metric	SCYNEXIS	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$51.19M	$12.02B	$7.08B	$12.96B
Dividend Yield	N/A	2.69%	2.57%	10.34%
P/E Ratio	-2.32	783.52	268.39	25.05
Price / Sales	2.33	750.79	559.59	69.51
Price / Cash	N/A	70.00	72.26	50.42
Price / Book	0.53	10.56	13.21	6.18
Net Income	-$8.61M	$2.78B	$3.44B	$347.05M
7 Day Performance	-6.20%	0.51%	2.07%	1.24%
1 Month Performance	10.50%	-1.50%	-0.26%	-0.65%
1 Year Performance	-29.64%	165.79%	70.30%	20.12%

SCYNEXIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCYX SCYNEXIS	3.6679 of 5 stars	$4.84 -6.2%	$24.00 +395.9%	-31.3%	$51.19M	$20.60M	N/A	60	Earnings Report
ANTX Anthem	1.8743 of 5 stars	$5.94 +6.5%	$9.00 +51.5%	+453.8%	$213.96M	N/A	N/A	N/A	Earnings Report
ACOG Alpha Cognition	4.3675 of 5 stars	$9.08 +7.7%	$16.00 +76.2%	-11.0%	$197.69M	$10.22M	N/A	N/A	Upcoming Earnings
SBTX Silverback Therapeutics	N/A	$5.46 +6.4%	N/A	-64.8%	$196.88M	N/A	N/A	83	High Trading Volume
IMUX Immunic	3.0199 of 5 stars	$14.05 -0.4%	$47.57 +238.6%	+82.3%	$191.36M	N/A	N/A	70	News Coverage Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCYX) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SCYNEXIS (SCYX) Competitors

SCYX vs. ANTX, ACOG, SBTX, IMUX, and NERV

How does SCYNEXIS compare to Anthem?

Summary

How does SCYNEXIS compare to Alpha Cognition?

Summary

How does SCYNEXIS compare to Silverback Therapeutics?

Summary

How does SCYNEXIS compare to Immunic?

Summary

How does SCYNEXIS compare to Minerva Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX vs. The Competition

SCYNEXIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SCYNEXIS (SCYX) Competitors

SCYX vs. ANTX, ACOG, SBTX, IMUX, and NERV

How does SCYNEXIS compare to Anthem?

Does the media refer more to ANTX or SCYX?

Which has preferable valuation & earnings, ANTX or SCYX?

Which has more risk and volatility, ANTX or SCYX?

Do analysts rate ANTX or SCYX?

Is ANTX or SCYX more profitable?

Do institutionals & insiders believe in ANTX or SCYX?

Summary

How does SCYNEXIS compare to Alpha Cognition?

Does the media prefer SCYX or ACOG?

Is SCYX or ACOG more profitable?

Which has more risk & volatility, SCYX or ACOG?

Do analysts prefer SCYX or ACOG?

Do insiders & institutionals hold more shares of SCYX or ACOG?

Which has stronger valuation and earnings, SCYX or ACOG?

Summary

How does SCYNEXIS compare to Silverback Therapeutics?

Does the media favor SCYX or SBTX?

Which has better valuation and earnings, SCYX or SBTX?

Is SCYX or SBTX more profitable?

Which has more volatility and risk, SCYX or SBTX?

Do analysts prefer SCYX or SBTX?

Do insiders and institutionals hold more shares of SCYX or SBTX?

Summary

How does SCYNEXIS compare to Immunic?

Do insiders and institutionals believe in IMUX or SCYX?

Which has more risk and volatility, IMUX or SCYX?

Do analysts prefer IMUX or SCYX?

Does the media prefer IMUX or SCYX?

Is IMUX or SCYX more profitable?

Which has higher valuation and earnings, IMUX or SCYX?

Summary

How does SCYNEXIS compare to Minerva Neurosciences?

Do analysts recommend NERV or SCYX?

Does the media prefer NERV or SCYX?

Is NERV or SCYX more profitable?

Do institutionals and insiders hold more shares of NERV or SCYX?

Which has preferable valuation & earnings, NERV or SCYX?

Which has more volatility and risk, NERV or SCYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX vs. The Competition

SCYNEXIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools